NASDAQ:GALT

Galectin Therapeutics Q1 2025 Earnings Results & Report

Galectin Therapeutics logo
$2.91 -0.11 (-3.64%)
As of 11/17/2026 04:00 PM Eastern

Galectin Therapeutics beat analyst earnings expectations in its Q1 2025 results, released May 15, 2025. The company reported EPS of -$0.15 versus the -$0.20 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
8:00 AM ET

Galectin Therapeutics EPS Results

Actual EPS
-$0.15
Consensus EPS
-$0.20
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 8 quarters

Galectin Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Galectin Therapeutics Q1 2025 Earnings FAQ

Galectin Therapeutics (NASDAQ:GALT) reported earnings of -$0.15 per share for Q1 2025, beating the consensus estimate of -$0.20. The report was announced on Thursday, May 15, 2025.

Galectin Therapeutics Earnings Headlines

Worse than socialism
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
Galectin Therapeutics Inc GALT
See More Galectin Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Galectin Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Galectin Therapeutics and other key companies, straight to your email.

About Galectin Therapeutics

Galectin Therapeutics (NASDAQ:GALT) is a clinical-stage biotechnology company developing treatments that target galectin proteins, particularly galectin-3. The company’s research focuses on diseases involving fibrosis and inflammation, as well as potential applications in cancer.

Its lead drug candidate, belapectin (GR-MD-02), is an investigational galectin-3 inhibitor. Galectin Therapeutics has studied belapectin for liver disease, including nonalcoholic steatohepatitis (NASH) with cirrhosis and complications related to portal hypertension, and has also explored its use in cancer treatment.

The company was previously known as Pro-Pharmaceuticals before adopting the Galectin Therapeutics name. Its work is centered on drug research and clinical development rather than the sale of marketed medicines.

View Galectin Therapeutics Profile